Published in Nat Protoc on April 12, 2012
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | NCT02963090
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
The cancer antigenome. EMBO J (2012) 1.78
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology (2014) 1.28
Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer (2016) 1.22
Beyond model antigens: high-dimensional methods for the analysis of antigen-specific T cells. Nat Biotechnol (2014) 1.22
Preparing unbiased T-cell receptor and antibody cDNA libraries for the deep next generation sequencing profiling. Front Immunol (2013) 1.12
BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology (2012) 1.04
Hierarchical Bayesian mixture modelling for antigen-specific T-cell subtyping in combinatorially encoded flow cytometry studies. Stat Appl Genet Mol Biol (2013) 0.95
T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. Clin Cancer Res (2014) 0.94
Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases. Eur J Immunol (2013) 0.92
5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. Blood Cancer J (2014) 0.89
Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int (2013) 0.86
Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters. Cancer Immunol Immunother (2015) 0.83
Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. Oncoimmunology (2013) 0.83
Engineering opportunities in cancer immunotherapy. Proc Natl Acad Sci U S A (2015) 0.82
Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nat Biotechnol (2016) 0.81
Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells. Cytometry A (2014) 0.81
Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma. J Cancer Res Clin Oncol (2015) 0.80
Literature classification for semi-automated updating of biological knowledgebases. BMC Genomics (2013) 0.80
Molecular imaging in tracking tumor-specific cytotoxic T lymphocytes (CTLs). Theranostics (2014) 0.80
Broadening the repertoire of melanoma-associated T-cell epitopes. Cancer Immunol Immunother (2015) 0.79
Development of a hypersensitive periodate-cleavable amino acid that is methionine- and disulfide-compatible and its application in MHC exchange reagents for T cell characterisation. Chembiochem (2013) 0.78
Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC. J Immunother Cancer (2017) 0.76
A Simple and Rapid Method for Quality Control of Major Histocompatibility Complex-Peptide Monomers by Flow Cytometry. Front Immunol (2017) 0.75
Clinically Relevant Reactivation of Polyomavirus BK (BKPyV) in HLA-A02-Positive Renal Transplant Recipients Is Associated with Impaired Effector-Memory Differentiation of BKPyV-Specific CD8+ T Cells. PLoS Pathog (2016) 0.75
Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma. Oncotarget (2017) 0.75
Mathematical Models for Immunology: Current State of the Art and Future Research Directions. Bull Math Biol (2016) 0.75
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science (2011) 15.45
Quality assurance for polychromatic flow cytometry. Nat Protoc (2006) 3.34
Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01
Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods (2009) 2.57
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47
Parasite stage-specific recognition of endogenous Toxoplasma gondii-derived CD8+ T cell epitopes. J Infect Dis (2008) 2.40
Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes (2010) 1.91
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology (2012) 1.78
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A (2008) 1.77
Simultaneous detection of many T-cell specificities using combinatorial tetramer staining. Nat Methods (2009) 1.67
Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods (2008) 1.62
Dissection of T-cell antigen specificity in human melanoma. Cancer Res (2012) 1.52
Discovery of CD8+ T cell epitopes in Chlamydia trachomatis infection through use of caged class I MHC tetramers. Proc Natl Acad Sci U S A (2008) 1.43
Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med (2005) 1.42
Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc (2009) 1.34
MHC multimer technology: current status and future prospects. Curr Opin Immunol (2005) 1.24
High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations. PLoS One (2011) 1.03
Detection of antigen-specific T cells on p/MHC microarrays. J Mol Recognit (2007) 1.01
Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J Autoimmun (2011) 1.00
Concurrent detection of circulating minor histocompatibility antigen-specific CD8+ T cells in SCT recipients by combinatorial encoding MHC multimers. PLoS One (2011) 0.90
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
Multistep synthesis of a radiolabeled imaging probe using integrated microfluidics. Science (2005) 2.83
Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods (2009) 2.57
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47
Diverse and heritable lineage imprinting of early haematopoietic progenitors. Nature (2013) 2.19
Intravital microscopy through an abdominal imaging window reveals a pre-micrometastasis stage during liver metastasis. Sci Transl Med (2012) 2.02
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood (2010) 2.01
Apoptosis threshold set by Noxa and Mcl-1 after T cell activation regulates competitive selection of high-affinity clones. Immunity (2010) 1.98
Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes (2010) 1.91
Antigen bias in T cell cross-priming. Science (2004) 1.82
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology (2012) 1.78
The cancer antigenome. EMBO J (2012) 1.78
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A (2008) 1.77
Analysis of protease activity in live antigen-presenting cells shows regulation of the phagosomal proteolytic contents during dendritic cell activation. J Exp Med (2002) 1.64
Dissection of T-cell antigen specificity in human melanoma. Cancer Res (2012) 1.52
Tissue-resident memory CD8+ T cells continuously patrol skin epithelia to quickly recognize local antigen. Proc Natl Acad Sci U S A (2012) 1.50
High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40
Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. J Virol (2005) 1.36
Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc (2009) 1.34
Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A (2009) 1.34
A closer look at proteolysis and MHC-class-II-restricted antigen presentation. Curr Opin Immunol (2002) 1.32
HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res (2013) 1.23
Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov (2005) 1.22
Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc Natl Acad Sci U S A (2003) 1.20
Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol Immunother (2011) 1.14
An early HIV mutation within an HLA-B*57-restricted T cell epitope abrogates binding to the killer inhibitory receptor 3DL1. J Virol (2011) 1.13
Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature (2016) 1.12
Immunogenicity of constitutively active V599EBRaf. Cancer Res (2004) 1.12
Pairing of T-cell receptor chains via emulsion PCR. Eur J Immunol (2013) 1.12
Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother (2012) 1.08
The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One (2009) 1.07
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med (2012) 1.06
Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo. J Immunol (2009) 1.06
Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol (2011) 1.04
Behavior and function of tissue-resident memory T cells. Adv Immunol (2012) 1.03
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res (2011) 1.02
Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice. Virology (2006) 1.02
Spontaneous immunity against Bcl-xL in cancer patients. J Immunol (2005) 1.00
High-throughput T-cell epitope discovery through MHC peptide exchange. Methods Mol Biol (2009) 1.00
Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J Autoimmun (2011) 1.00
Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion. J Invest Dermatol (2012) 0.98
Immunogenicity of Bcl-2 in patients with cancer. Blood (2004) 0.98
MHC-based detection of antigen-specific CD8+ T cell responses. Cancer Immunol Immunother (2010) 0.98
Human cancer regression antigens. Curr Opin Immunol (2013) 0.96
T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. Clin Cancer Res (2014) 0.94
Integrated microfluidic devices for combinatorial cell-based assays. Biomed Microdevices (2009) 0.93
Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy (2010) 0.93
Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther (2009) 0.91
Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. J Control Release (2009) 0.86
The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. Cancer Immunol Immunother (2012) 0.86
Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures. Cell Immunol (2011) 0.84
Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression. Blood (2011) 0.84
Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype. Hum Gene Ther Methods (2014) 0.83
Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. Oncoimmunology (2013) 0.83
High frequency of T cells specific for cryptic epitopes in melanoma patients. Oncoimmunology (2013) 0.82
Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7. Int J Cancer (2011) 0.82
Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells. Cytometry A (2014) 0.81
Shift from systemic to site-specific memory by tumor-targeted IL-2. J Immunol (2004) 0.81
RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol Immunother (2010) 0.81
Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient. Cancer Immunol Immunother (2006) 0.81
HLA micropolymorphisms strongly affect peptide-MHC multimer-based monitoring of antigen-specific CD8+ T cell responses. J Immunol (2013) 0.81
Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion. Cancer Immunol Immunother (2012) 0.81
Broadening the repertoire of melanoma-associated T-cell epitopes. Cancer Immunol Immunother (2015) 0.79
Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses. Hum Gene Ther (2012) 0.79
Characterization of T-cell responses against IκBα in cancer patients. Oncoimmunology (2012) 0.79
Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients. Clin Cancer Res (2009) 0.79
Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proc Natl Acad Sci U S A (2013) 0.78
Synthetic vehicles for DNA vaccination. J Drug Target (2010) 0.78
Lipopolysaccharide contamination in intradermal DNA vaccination: toxic impurity or adjuvant? Int J Pharm (2009) 0.77
Longitudinal immune monitoring of patients receiving intratumoral injection of a MART-1 T-cell receptor-transduced cell line (C-Cure 709). Cytotherapy (2009) 0.76
Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients. Cancer Immunol Immunother (2009) 0.76
Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients. Hum Immunol (2008) 0.75
"Immunotherapy of cancer: present status and future promise": Danish Cancer Society Symposium, Copenhagen, Denmark, 23rd-25th September 2013. Cancer Immunol Immunother (2014) 0.75
Identification of an HLA-A3-restricted cytotoxic T lymphocyte (CTL) epitope from ML-IAP. J Invest Dermatol (2004) 0.75
A promiscuous survivin-derived T-cell epitope restricted to the HLA-A3 super-type alleles. J Invest Dermatol (2012) 0.75
Toward next-generation cancer immunotherapy: 10th annual meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 23-25, 2012. Cancer Immunol Immunother (2013) 0.75
Toward the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14-16, 2013. Cancer Immunol Immunother (2013) 0.75
Cytokine fusion protein treatment. Recent Results Cancer Res (2002) 0.75